Abbott Laboratories Inc. and AbbVie Inc., the last defendants in the litigation over “low testosterone,” have reached a global settlement that resolves more than 4,000 cases.

In an order on Monday, U.S. District Judge Matthew Kennelly of the Northern District of Illinois said the “parties have entered into a confidential term sheet regarding a potential global settlement.” He stayed all cases against Abbott and AbbVie, and canceled a Thursday status hearing, “so that the parties may devote their efforts to finalizing a master settlement agreement.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]